Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
2015 (English)In: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 35, no 5Article in journal (Refereed) Published
Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy mainly localized to the pleura. Malignant mesothelioma grows highly invasive into surrounding tissue and has a low tendency to metastasize. The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. The present review aims at describing available data from randomized trials considering systemic medical treatment for this patient category.
Place, publisher, year, edition, pages
2015. Vol. 35, no 5
Cancer and Oncology
IdentifiersURN: urn:nbn:se:umu:diva-120020PubMedID: 25964522OAI: oai:DiVA.org:umu-120020DiVA: diva2:926213